# Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Canonical URL: https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-european-union-for-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Source: Arrowhead Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.arrowheadpharma.com
## Summary

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing

## Article Body
REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing
## Recent Company News
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-european-union-for-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-host-a-webinar-on-its-cardiometabolic-pipeline-as-part-i-of-the-2026-summer-series-of-randd-webinars) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-clinical-data-on-rnai-based-obesity-and-mash-candidate-aro-inhbe-at-easl-2026) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress) — Source: Arrowhead Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)